The pharmaceutical industry in Ireland is experiencing significant growth, particularly in the production and export of weight-loss medications. Recent analyses indicate that exports of essential components for these drugs have surged, now accounting for 20% of Ireland’s total goods exports, valued at €51 billion. This trend highlights the remarkable transformation of the sector within just a few years.
Record Export Growth
A report from Goodbody chief economist Dermot O’Leary reveals a striking growth trajectory for pharmaceutical exports. In 2025, total pharmaceutical exports reached €139 billion, representing an impressive 53% of all Irish goods exports. This marks the highest export percentage ever recorded for the sector in Ireland, underscoring its importance to the national economy.
Key Ingredients Driving Success
The rise in exports is largely driven by the production of GLP-1 drugs, including semaglutide and tirzepatide. These active ingredients are critical for medications like Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly. The export value of hormones and their derivatives skyrocketed from €14 billion in 2024 to €51 billion in 2025, illustrating the escalating demand for these innovative treatments.
Eli Lilly’s Expanding Influence
Eli Lilly’s impact on the Irish pharmaceutical landscape is particularly noteworthy. The report highlighted that nearly 40% of Ireland’s pharmaceutical exports to the United States were directed towards Indiana, the home of Eli Lilly’s major manufacturing facilities. With two operational sites in Ireland—one in Kinsale and another in Limerick—Lilly has solidified its role as a key player in the global pharmaceutical market.
Investment in Future Production
Eli Lilly has pledged a substantial investment of $9 billion to enhance its pharmaceutical manufacturing capabilities in Lebanon, Indiana. This investment is aimed specifically at increasing the production of GLP-1 drugs and their key active pharmaceutical ingredients (APIs), such as tirzepatide. This commitment indicates a strong belief in the sustained demand for these weight-loss medications.
Rising Demand for GLP-1 Drugs
The uptake of GLP-1 medications continues to rise in the United States. Eli Lilly’s chief financial officer recently announced plans to launch a new oral obesity drug, orforglipron, pending FDA approval. Anticipated to enter the market as early as the second quarter, Lilly has already prepared a significant pre-launch inventory, positioning itself to meet the growing consumer demand effectively.
Employment and Economic Impact
The Goodbody report, presented at the Irish Pharmaceutical Healthcare Association (IPHA) conference, also emphasized the industry’s role in job creation. Approximately 75,000 individuals are employed directly and indirectly within the pharmaceutical sector in Ireland, with employment growth in this field outpacing the overall labor market. Furthermore, the industry contributed around €6 billion in taxes in 2023, accounting for about 18% of total corporation tax receipts.
Ireland’s Competitive Position in Europe
In 2024, Ireland ranked as Europe’s second-largest pharmaceutical exporter, trailing only Germany. The report illustrates the critical role the Irish pharmaceutical sector plays not only in the national economy but also in the broader European and global healthcare landscape. As highlighted by IPHA president Shane Ryan, the challenge lies in ensuring that innovation is accessible to patients promptly.
Regional Development and Investment
The report also noted the importance of the pharmaceutical sector in driving regional development, particularly in the South-East and South-West of Ireland. The concentration of industry activity in these areas has stimulated investment and economic growth, benefiting local communities.
Future of Innovation and Access
With the recent framework agreement established by the IPHA, there is optimism for faster access to innovative medicines for patients in Ireland. IPHA chief executive Oliver O’Connor emphasized the potential for the country’s economic strength in the pharmaceutical sector to translate into tangible benefits for patients.
In conclusion, the remarkable growth of Ireland’s pharmaceutical sector, particularly in the weight-loss drug market, signals a promising future for both the industry and public health. As the sector continues to expand, it holds the potential to enhance patient access to innovative therapies, while simultaneously bolstering the Irish economy.
- Key exports in weight-loss drug manufacturing have surged to €51 billion.
- Eli Lilly is a major contributor to this growth, with significant investments in production.
- The Irish pharmaceutical sector employs around 75,000 people, growing faster than the overall job market.
- Ireland ranks as Europe’s second-largest pharmaceutical exporter, highlighting its global significance.
- New agreements aim to expedite patient access to groundbreaking medicines.
Read more → www.irishexaminer.com